Novan’s Drug Substance Demonstrates Inhibition of HPV-18 Virus Production

MORRISVILLE, N.C., July 24, 2019 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that independently generated preclinical data which demonstrated the antiviral effects of the Company’s nitric oxide-releasing macromolecule, NVN1000, on human papillomavirus (HPV) infections has been published in Antiviral Research. The study was conducted by a research team from the Department of Biochemistry and Molecular Genetics at the University of Alabama at Birmingham led by N. Sanjib Banerjee, Ph.D., Thomas R. Broker, Ph.D., Founding President of the International Papillomavirus Society, and Louise T. Chow, PhD, Member of the U.S. National Academy of Sciences and of Academia Sinica (Taiwan).